Loading...
•
Sep 30, 2023
Caribou Biosciences Q3 2023 Earnings Report
Caribou Biosciences reported financial results for Q3 2023 and provided a business update.
Key Takeaways
Caribou Biosciences reported Q3 2023 financial results, highlighting advancements in their pipeline programs, including CB-010, CB-011, and CB-012. The company's cash, cash equivalents, and marketable securities totaled $396.7 million, expected to fund operations into Q4 2025.
CB-010 ANTLER Phase 1 trial continues enrolling second-line r/r LBCL patients in dose expansion; plan to share FDA feedback by year-end 2023 and report initial dose expansion data in H1 2024.
CB-011 CaMMouflage Phase 1 trial enrollment ongoing in r/r MM patients.
CB-012 AMpLify Phase 1 trial site activation underway following recent IND clearance; expect to initiate enrollment by mid-2024 in r/r AML patients.
$396.7 million in cash, cash equivalents, and marketable securities expected to fund the current operating plan into Q4 2025.
Forward Guidance
Caribou plans to meet with the FDA to discuss a potential pivotal clinical trial in second-line LBCL patients and plans to share FDA feedback by year-end 2023. The Company also plans to report initial dose expansion data in second-line LBCL patients from the ongoing ANTLER trial in H1 2024. Caribou plans to provide updates on dose escalation as the CaMMouflage Phase 1 clinical trial in r/r MM advances. Caribou plans to initiate patient enrollment in the AMpLify Phase 1 clinical trial in r/r AML by mid-2024.
Positive Outlook
- Plan to share FDA feedback by year-end 2023.
- Report initial dose expansion data in H1 2024.
- Continue to enroll second-line LBCL patients in the dose expansion portion of the ongoing ANTLER Phase 1 clinical trial.
- Provide updates on dose escalation as the CaMMouflage Phase 1 clinical trial in r/r MM advances.
- Initiate patient enrollment in the AMpLify Phase 1 clinical trial in r/r AML by mid-2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...